ALNYLAM PHARMACEUTICALS, INC. — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 58/100
What the filing says
Q3 2026 net product revenues grew 52% YoY to $1,292M, driven by AMVUTTRA ($1,130M, +65% YoY) and ONPATTRO ($20M, -50% YoY) in TTR franchise, plus Rare segment at $142M (+12% YoY). TRITON-CM Phase 3 enrollment target expanded from 1,750 to ~2,250 patients; nucresiran still expected to launch by 2030. Brezosiran (Huntington's) Phase 1 showed 60-64% mean CSF huntingtin reduction; pivotal trial planned for 2027. Full-year 2026 guidance reaffirmed: $4.7-5.1B total net product revenues. Cash position strengthened to $3.6B.
Why this rating
Strong 52% product revenue growth and robust cash generation moderate headwinds from higher COGS and R&D spending. Enrollment expansion and pipeline advancement support long-term growth but lack near-term surprise. Relative to $42.6B market cap, ~$1.3B quarterly revenue is material but not transformational.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.